CO5261615A1 - Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas - Google Patents
Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronasInfo
- Publication number
- CO5261615A1 CO5261615A1 CO00091748A CO00091748A CO5261615A1 CO 5261615 A1 CO5261615 A1 CO 5261615A1 CO 00091748 A CO00091748 A CO 00091748A CO 00091748 A CO00091748 A CO 00091748A CO 5261615 A1 CO5261615 A1 CO 5261615A1
- Authority
- CO
- Colombia
- Prior art keywords
- straight
- alkenyl
- substituted
- branched
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto de la fórmula <EMI FILE="00091748_1" ID="1" IMF=JPEG >o sal farmacéuticamente aceptable, solvato, prodroga farmacéuticamente aceptable o un metabolito farmacéuticamente activo del mismo, donde: A es C3-C5 alquileno opcionalmente sustituido con uno o más sustituyentes adecuados y opcionalmente cualquiera de los grupos CH2 del grupo alquileno puede ser sustituido por O, S, SO o SO2;B es <EMI FILE="00091748_2" ID="2" IMF=JPEG >donde E y G son independientemente Ar, H, C1-C6 alquilo recto o ramificado, C1-C6 alquenilo recto o ramificado, C1-C6, alquilo o alquenilo recto o ramificado que está sustituido con un C5-C7 cicloalkilo, C1-C6 alkilo o alkenilo recto o ramificado que está sustituido con un C5-C7 cicloalkenilo, o Ar sustituido con C1-C6 <EMI FILE="00091748_3" ID="3" IMF=JPEG >alkilo o alkenilo recto o ramificado, donde, en cada caso, uno o dos de los grupos CH2 de las cadenas del alkilo o alkenilo pueden ser reemplazados por 1-2 componentes seleccionados del grupo consistente de oxígeno, azufre, SO y SO2, o donde J es H, C1-C6 alkilo recto o ramificado o C1-C6 alkenilo recto o ramificado; K es Ar o un cicloalkilo de 5-7 miembros sustituido con sustituyentes en las posiciones 3 y 4 que son independientemente seleccionados del grupo consistente de H, OH, -O-(CH2)m-alkilo, -O-(CH2)m-alkenilo y carbonilo, donde m es 1-4; donde Ar es seleccionado del grupo consistente de fenilo, 1-naftilo, 2-naftilo, 2-furilo, 3-furilo, 2-tienilo, 3-tienilo, 2-piridilo, 3-piridilo, 4-piridilo, sistemas de anillos heterocíclicos, monocíclicos o bicíclicos ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16824699P | 1999-12-01 | 1999-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261615A1 true CO5261615A1 (es) | 2003-03-31 |
Family
ID=22610717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00091748A CO5261615A1 (es) | 1999-12-01 | 2000-11-30 | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas |
Country Status (18)
Country | Link |
---|---|
US (1) | US6544987B2 (es) |
EP (1) | EP1237869A1 (es) |
JP (1) | JP2004500355A (es) |
AR (1) | AR029411A1 (es) |
AU (1) | AU1810001A (es) |
BR (1) | BR0016150A (es) |
CA (1) | CA2389368A1 (es) |
CO (1) | CO5261615A1 (es) |
DO (1) | DOP2000000107A (es) |
GT (1) | GT200000203A (es) |
HK (1) | HK1048987A1 (es) |
HN (1) | HN2000000268A (es) |
MX (1) | MXPA02005510A (es) |
PA (1) | PA8508001A1 (es) |
PE (1) | PE20011101A1 (es) |
SV (1) | SV2002000233A (es) |
UY (1) | UY26464A1 (es) |
WO (1) | WO2001040185A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
EP1567487A4 (en) * | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
CN101006076B (zh) * | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
US7544171B2 (en) * | 2004-10-22 | 2009-06-09 | General Patent Llc | Methods for promoting nerve regeneration and neuronal growth and elongation |
US7988648B2 (en) * | 2005-03-04 | 2011-08-02 | General Patent, Llc | Pancreas regeneration treatment for diabetics using extracorporeal acoustic shock waves |
WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
EP1928886B1 (en) | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
US7419394B2 (en) * | 2005-11-11 | 2008-09-02 | Rockwell Automation Technologies, Inc. | Electrical system having withdrawable unit with maintained control and communication connection |
JP2009521468A (ja) * | 2005-12-24 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Abc輸送体の調節因子としてのキノリン−4−オン誘導体 |
JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
CN101569864B (zh) * | 2008-04-29 | 2011-08-03 | 中山大学 | 手性磺胺类有机小分子催化剂及其应用 |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
US11389372B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
US11389373B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to prevent or treat opioid addiction |
US11458069B2 (en) | 2016-04-18 | 2022-10-04 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to treat medical conditions using reflexology zones |
US11389370B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves |
US11389371B2 (en) | 2018-05-21 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
US11345659B2 (en) * | 2018-01-30 | 2022-05-31 | Board Of Regents, The University Of Texas System | Pipecolic esters for inhibition of the proteasome |
EP4361148A1 (en) * | 2021-06-25 | 2024-05-01 | Albius Sciences Alpha Private Limited | Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0187500B1 (en) | 1984-12-20 | 1993-04-28 | The Upjohn Company | Monobactams |
US5192773A (en) | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5244905A (en) | 1990-08-31 | 1993-09-14 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives |
US5219851A (en) | 1991-03-05 | 1993-06-15 | Warner-Lambert Company | Tetrahydroisoquinoline-type renin inhibiting peptides |
DE4141218A1 (de) | 1991-12-13 | 1993-06-17 | Luitpold Werk Chem Pharm | Thiadiazincarbonsaeureamidderivate, verfahren zu ihrer herstellung und arzneimittel |
DE4217719A1 (de) | 1992-05-29 | 1993-12-02 | Bayer Ag | Zweifach heterocyclisch substituierte Sulfonylamino(thio)carbonylverbindungen |
US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US5612350A (en) | 1993-11-30 | 1997-03-18 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
US5541168A (en) | 1994-12-02 | 1996-07-30 | Sterling Winthrop Inc. | Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
US5494925A (en) | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
US5556909A (en) | 1994-12-02 | 1996-09-17 | Sanofi Winthrop Inc. | Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof |
US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US5614547A (en) | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
GB9521322D0 (en) | 1995-10-17 | 1995-12-20 | Sandoz Ltd | Organic compounds |
US5801197A (en) | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
DK0861236T4 (da) | 1995-11-13 | 2006-12-18 | Sanofi Aventis Deutschland | Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer |
DE19542189A1 (de) | 1995-11-13 | 1997-05-15 | Hoechst Ag | Cyclische N-substituierte alpha-Iminohydroxamsäuren |
US5786378A (en) | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
US5801187A (en) | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
US5935989A (en) | 1996-12-31 | 1999-08-10 | Gpi Nil Holdings Inc. | N-linked ureas and carbamates of heterocyclic thioesters |
US5874449A (en) | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
JP3563411B2 (ja) | 1997-01-23 | 2004-09-08 | エフ・ホフマン−ラ ロシュ アーゲー | スルファミド−メタロプロテアーゼ阻害剤 |
US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
ZA98825B (en) | 1997-02-27 | 1998-10-19 | Guilford Pharm Inc | Method of using neurotrophic carbamates and ureas |
US5846979A (en) | 1997-02-28 | 1998-12-08 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic esters, amides, thioesters, and ketones |
GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
US6121280A (en) * | 1998-03-24 | 2000-09-19 | Pfizer Inc. | Azabicyclic rotomase inhibitors |
AU743199B2 (en) | 1998-06-02 | 2002-01-24 | Bristol-Myers Squibb Company | Neurotrophic difluoroamide agents |
US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
CZ2001126A3 (cs) | 1998-07-21 | 2002-01-16 | Warner-Lambert Company | Společné účinky ACAT a MMP inhibitorů při léčbě aterosklerotických lézí |
EP1127049A1 (en) | 1998-09-18 | 2001-08-29 | GPI NIL Holdings, Inc. | Bridged heterocyclic derivatives |
AU3221300A (en) | 1999-02-03 | 2000-08-25 | Schering Aktiengesellschaft | Carboxylic acid derivatives, process for their preparation and their use as rotamase enzyme activity inhibitors |
-
2000
- 2000-11-30 GT GT200000203A patent/GT200000203A/es unknown
- 2000-11-30 CO CO00091748A patent/CO5261615A1/es not_active Application Discontinuation
- 2000-11-30 DO DO2000000107A patent/DOP2000000107A/es unknown
- 2000-12-01 SV SV2000000233A patent/SV2002000233A/es unknown
- 2000-12-01 HN HN2000000268A patent/HN2000000268A/es unknown
- 2000-12-01 EP EP00980901A patent/EP1237869A1/en not_active Withdrawn
- 2000-12-01 AR ARP000106371A patent/AR029411A1/es not_active Application Discontinuation
- 2000-12-01 BR BR0016150-0A patent/BR0016150A/pt not_active Application Discontinuation
- 2000-12-01 JP JP2001541871A patent/JP2004500355A/ja not_active Abandoned
- 2000-12-01 MX MXPA02005510A patent/MXPA02005510A/es active IP Right Grant
- 2000-12-01 PA PA20008508001A patent/PA8508001A1/es unknown
- 2000-12-01 US US09/726,314 patent/US6544987B2/en not_active Expired - Fee Related
- 2000-12-01 WO PCT/US2000/032679 patent/WO2001040185A1/en active Application Filing
- 2000-12-01 CA CA002389368A patent/CA2389368A1/en not_active Abandoned
- 2000-12-01 AU AU18100/01A patent/AU1810001A/en not_active Abandoned
- 2000-12-01 PE PE2000001288A patent/PE20011101A1/es not_active Application Discontinuation
- 2000-12-01 UY UY26464A patent/UY26464A1/es not_active Application Discontinuation
-
2003
- 2003-01-29 HK HK03100726.8A patent/HK1048987A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2389368A1 (en) | 2001-06-07 |
JP2004500355A (ja) | 2004-01-08 |
BR0016150A (pt) | 2002-08-13 |
US6544987B2 (en) | 2003-04-08 |
AU1810001A (en) | 2001-06-12 |
PA8508001A1 (es) | 2002-08-26 |
GT200000203A (es) | 2002-05-24 |
HN2000000268A (es) | 2003-12-11 |
SV2002000233A (es) | 2002-12-02 |
AR029411A1 (es) | 2003-06-25 |
HK1048987A1 (zh) | 2003-04-25 |
PE20011101A1 (es) | 2001-11-29 |
WO2001040185A1 (en) | 2001-06-07 |
WO2001040185B1 (en) | 2001-11-15 |
UY26464A1 (es) | 2001-07-31 |
EP1237869A1 (en) | 2002-09-11 |
MXPA02005510A (es) | 2004-09-10 |
US20020061881A1 (en) | 2002-05-23 |
DOP2000000107A (es) | 2002-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261615A1 (es) | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas | |
CO5261559A1 (es) | Antagonistas de neurokinina selectivos | |
BR9707333A (pt) | Dihidrobenzofurano e compostos relacionados úteis como agentes antinflamatórios | |
AR024077A1 (es) | Compuestos antibacterianos | |
UY26093A1 (es) | Inhibidores de ap2 de bifenilos que contienen compuestos heterociclicos y metodo | |
BR0309447A (pt) | Composto, agente, processos para a preparação dos mesmos, e para o combate do crescimento de plantas indesejadas, e, uso do composto | |
ECSP066760A (es) | Derivado de 4-oxopirimidina de anillos condensados | |
CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
AR014948A1 (es) | Compuestos macrolidos, composiciones, su uso para la manufactura de medicamentos y metodo para prepararlos. | |
UY28132A1 (es) | Derivados de pirrolopirimidina | |
CO4650136A1 (es) | Derivados 4-amino de acido micofenolico | |
NO20026253D0 (no) | Organiske forbindelser | |
CO5580771A2 (es) | Antagonistas ccr5 como agentes terapeuticos | |
PE20080768A1 (es) | Compuestos de isoindolina 5-sustituidos | |
ES2112332T3 (es) | Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico. | |
EA200100983A1 (ru) | Производные 13-метилэритромицина | |
RS51249B (sr) | Upotreba derivata sulfonamida sa benzo-fuzionisanim heterociklom za tretman bola | |
EA200201201A1 (ru) | Соединения с сульфамидной группой и содержащие эти соединения фармацевтические композиции | |
ES2111930T3 (es) | Antagonistas del acido amp y procedimientos de tratamiento con la ayuda de estos. | |
CO5261527A1 (es) | Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina | |
BR9707250A (pt) | Dihidrobenzofurano e compostos correlatos úteis como agentes antiinflamatórios | |
CO5251424A1 (es) | Oxazinquinolonas utiles en el tratamiento de infecciones virales | |
AR045816A1 (es) | Derivados de carboxamida | |
BR9707266A (pt) | Compostos dihidrobenzofurano úteis como agentes antiinflamatórios | |
AR028968A1 (es) | Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |